Correction of functional disorders in ADMA-like preeclampsia with derivatives of the peptide imitating erythropoietin α-helix B

Objective. The aim of the study is to investigate the correction of functional disorders in ADMA-like preeclampsia with derivatives of the peptide imitating erythropoietin α-helix B. Materials and methods. The study was performed in 120 white female Wistar rats weighing 250-300 g. ADMA-like preeclampsia was used as experimental preeclampsia. To assess the effectiveness of the pharmacological agents used, blood pressure, microcirculation in the placenta, and proteinuria were recorded, the content of final NO metabolites in the blood plasma was determined, and the coefficient of endothelial dysfunction was calculated. 50 μg / kg polypeptides (P-αB3 and P-αB4) were used as pharmacological agents, obtained by attaching to the original 11-amino acid peptide PHBSP [PubChem CID: 91810664], which is the amino acid chain Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (QEQLERALNSS) of KGD group from different ends of the chain. Results. The use of the studied derivatives of peptide imitating erythropoietin α-helix B with ADMA-like preeclampsia leads to a pronounced correction of disorders. The greatest effect was observed with the introduction of the peptide with the laboratory code P-αB4. A significant decrease in systolic and diastolic pressure was noted, respectively, improved microcirculation in the placenta, restoration of the NO-synthesizing function of the endothelium, and a decrease in proteinuria. Conclusion. The results obtained indicate the prospect of further research on the effectiveness of short-chain derivatives of erythropoietin imitating its α-helix B for the correction of functional disorders in preeclampsia.